Inhibitory effect of NO-releasing ciprofloxacin (NCX 976) on Mycobacterium tuberculosis survival

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 7, 2003, Pages 2299-2302

  Ciccone, R ^a   Mariani, F ^b   Cavone, A ^a   Persichini, T ^c   Venturini, G ^c   Ongini, E ^d   Colizzi, V ^a   Colasanti, M ^c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b CNR   (Italy)

^c ROMA TRE UNIVERSITY   (Italy)

^d Nicox Research Institute   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CIPROFLOXACIN 2 METHOXY 4 [3 [4' (NITROOXY)BUTOXY] 3 OXO 1 PROPENYL]PHENYL ESTER; NCX 976; NITRIC OXIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL;

ANTI-INFECTIVE AGENTS; CELL-FREE SYSTEM; CIPROFLOXACIN; DRUG DESIGN; HUMANS; MACROPHAGES; MYCOBACTERIUM TUBERCULOSIS; NITRIC OXIDE;

EID: 0037974621     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.7.2299-2302.2003     Document Type: Article

References (18)

1. Akaike, T., and H. Maeda. 2000. Nitric oxide and virus infection. Immunology 101:300-308.
2. Alangaden, G. J., and S. A. Lerner. 1997. The clinical use of fluoroquinolones for the treatment of mycobacterial diseases. Clin. Infect. Dis. 25:1213-1221.
3. Chan, E. D., J. Chan, and N. W. Schluger. 2001. What is the role of nitric oxide in murine and human host defense against tuberculosis? Current knowledge. Am. J. Respir. Cell Mol. Biol. 25:606-612.
4. Clark, I. A., and K. A. Rockett. 1996. Nitric oxide and parasitic disease. Adv. Parasitol. 37:1-56.
5. Colasanti, M., T. Persichini, G. Venturini, and P. Ascenzi. 1999. S-nitrosylation of viral proteins: molecular bases for antiviral effect of nitric oxide. IUBMB Life 48:25-31.
6. Couture, M., S. R. Yeh, B. A. Wittenberg, J. B. Wittenberg, Y. Ouellet, D. L. Rousseau, and M. Guertin. 1999. A cooperative oxygen-binding hemoglobin from Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA 96:11223-11228.
7. del Soldato, P., R. Sorrentino, and A. Pinto. 1999. NO-aspirins: a class of new anti-inflammatory and antithrombotic agents. Trends Pharmacol. Sci. 20:319-323.
8. Hu, Y., P. D. Butcher, J. A. Mangan, M. A. Rajandream, and A. R. Coates. 1999. Regulation of hmp gene transcription in Mycobacterium tuberculosis: effects of oxygen limitation and nitrosative and oxidative stress. J. Bacteriol. 181:3486-3493.
9. Huttunen, K., J. Jussila, M. R. Hirvonen, E. Iivanainen, and M. L. Katila. 2001. Comparison of mycobacteria-induced cytotoxicity and inflammatory responses in human and mouse cell lines. Inhal. Toxicol. 13:977-991.
10. Long, R., B. Light, and J. A. Talbot. 1999. Mycobacteriocidal action of exogenous nitric oxide. Antimicrob. Agents Chemother. 43:403-405.
11. Mariani, F., G. Cappelli, G. Riccardi, and V. Colizzi. 2000. Mycobacterium tuberculosis H37Rv comparative gene-expression analysis in synthetic medium and human macrophage. Gene 253:281-291.
12. Nathan, C., and M. U. Shiloh. 2000. Reactive oxygen and nitrogen intermediates in the relationship between mammalian hosts and microbial pathogens. Proc. Natl. Acad. Sci. USA 97:8841-8848.
13. Raupach, B., and S. H. Kaufmann. 2001. Immune responses to intracellular bacteria. Curr. Opin. Immunol. 13:417-428.
14. Scanga, C. A., V. P. Mohan, K. Tanaka, D. Alland, J. L. Flynn, and J. Chan. 2001. The inducible nitric oxide synthase locus confers protection against aerogenic challenge of both clinical and laboratory strains of Mycobacterium tuberculosis in mice. Infect. Immun. 69:7711-7717.
15. Shiloh, M. U., and C. F. Nathan. 2000. Reactive nitrogen intermediates and the pathogenesis of Salmonella and mycobacteria. Curr. Opin. Microbiol. 3:35-42.
16. Tomioka, H. 2000. Prospects for development of new antimycobacterial drugs. J. Infect. Chemother. 6:8-20.
17. Tomioka, H., K. Sato, H. Kajitani, T. Akaki, and S. Shishido. 2000. Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Antimicrob. Agents Chemother. 44:283-286.
18. Zahrt, T. C., and V. Deretic. 2002. Reactive nitrogen and oxygen intermediates and bacterial defenses: unusual adaptations in Mycobacterium tuberculosis. Antioxid. Redox. Signal. 4:141-159.